Literature DB >> 17586680

EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder.

A Brunner1, M Prelog, I Verdorfer, A Tzankov, G Mikuz, C Ensinger.   

Abstract

BACKGROUND: EpCAM is an adhesion molecule of the basolateral membranes in a variety of epithelial cells. Over-expression has been detected in many epithelial tumours and has been associated with high stage, high grade and a worse survival in some tumour types. AIMS: To assess the prognostic value of EpCAM in urothelial carcinoma of the bladder.
METHODS: EpCAM expression was analysed by immunohistochemistry using a monoclonal antibody (clone VU-1D9) on a tissue microarray comprising 99 urothelial carcinomas of the bladder diagnosed between 1994 and 1997.
RESULTS: A significant relationship between high grade, advanced stage, and EpCAM expression was found, and expression of EpCAM was associated with a worse overall survival when compared to EpCAM negative tumours (p = 0.033). Multivariate analysis showed that EpCAM expression was not an independent prognostic factor for overall survival in urothelial carcinoma of the bladder.
CONCLUSION: EpCAM expression is associated with advanced stage, high grade and poor overall survival in urothelial carcinoma of the bladder, but lacks an independent prognostic significance. The strong association with high grade tumours suggests a possible role during tumour progression and makes EpCAM a potential target for antibody mediated therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17586680     DOI: 10.1136/jcp.2007.049460

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  25 in total

1.  A high-content screen for small-molecule regulators of epithelial cell-adhesion molecule (EpCAM) cleavage yields a robust inhibitor.

Authors:  Jana Ylva Tretter; Kenji Schorpp; Elke Luxenburger; Johannes Trambauer; Harald Steiner; Kamyar Hadian; Olivier Gires; Dierk Niessing
Journal:  J Biol Chem       Date:  2018-04-26       Impact factor: 5.157

Review 2.  Molecular imaging with nanoparticles: giant roles for dwarf actors.

Authors:  Paul Debbage; Werner Jaschke
Journal:  Histochem Cell Biol       Date:  2008-09-30       Impact factor: 4.304

3.  Multiparametric Biomechanical and Biochemical Phenotypic Profiling of Single Cancer Cells Using an Elasticity Microcytometer.

Authors:  Shuhuan Hu; Guangyu Liu; Weiqiang Chen; Xiang Li; Wei Lu; Raymond H W Lam; Jianping Fu
Journal:  Small       Date:  2016-03-01       Impact factor: 13.281

4.  [Bladder cancer update: what was new at the 2010 annual congress of the German Association of Urology in Düsseldorf?].

Authors:  R Nawroth; A Hartmann; P J Olbert; A S Merseburger; R Stöhr; R Knüchel; M Retz; S Füssel
Journal:  Urologe A       Date:  2011-02       Impact factor: 0.639

5.  Functional polymorphism in the EpCAM gene is associated with occurrence and advanced disease status of cervical cancer in Chinese population.

Authors:  Min Hu; Lan Jian; Liyuan Zhang; Jiang Zheng; Yonghe You; Jieqiong Deng; Hua Li; Yifeng Zhou
Journal:  Mol Biol Rep       Date:  2012-02-10       Impact factor: 2.316

Review 6.  Antibody-Drug Conjugates in Uro-Oncology.

Authors:  Dawid Sigorski; Paweł Różanowski; Ewa Iżycka-Świeszewska; Katarzyna Wiktorska
Journal:  Target Oncol       Date:  2022-05-14       Impact factor: 4.864

7.  EPCAM and TROP2 share a role in claudin stabilization and development of intestinal and extraintestinal epithelia in mice.

Authors:  Roman Szabo; Jerrold M Ward; Ferruh Artunc; Thomas H Bugge
Journal:  Biol Open       Date:  2022-07-11       Impact factor: 2.643

8.  Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.

Authors:  Steven Christopher Smith; Brian Nicholson; Matthew Nitz; Henry F Frierson; Mark Smolkin; Garret Hampton; Wael El-Rifai; Dan Theodorescu
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.

Authors:  Mark Kowalski; Joycelyn Entwistle; Jeannick Cizeau; Demi Niforos; Shauna Loewen; Wendy Chapman; Glen C MacDonald
Journal:  Drug Des Devel Ther       Date:  2010-11-15       Impact factor: 4.162

Review 10.  Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.

Authors:  Richard T Bryan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-02-05       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.